{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:39:32Z","timestamp":1791329972068,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00259-011-2021-8","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T07:25:47Z","timestamp":1326785147000},"page":"621-631","source":"Crossref","is-referenced-by-count":229,"title":["Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment"],"prefix":"10.1007","volume":"39","author":[{"given":"V.","family":"Camus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Payoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Desgranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ch\u00e9telat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"de La Sayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Cottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vercouillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Eustache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Guilloteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"2021_CR1","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington DC: American Psychiatric Association; 2000."},{"key":"2021_CR2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"2021_CR3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"2021_CR4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999;52:1158\u201365.","journal-title":"Neurology"},{"key":"2021_CR5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734\u201346.","journal-title":"Lancet Neurol"},{"key":"2021_CR6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u2013279","journal-title":"Alzheimers Dement"},{"key":"2021_CR7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"2021_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456\u201365","journal-title":"Neurobiol Aging"},{"key":"2021_CR9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363\u201372.","journal-title":"Lancet Neurol"},{"key":"2021_CR10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446\u201352.","journal-title":"Neurology"},{"key":"2021_CR11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193\u20139.","journal-title":"Neurology"},{"key":"2021_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2967\/jnumed.106.037556","volume":"48","author":"Y Kudo","year":"2007","unstructured":"Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer\u2019s disease patients. J Nucl Med. 2007;48:553\u201361.","journal-title":"J Nucl Med"},{"key":"2021_CR13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2009.06.005","volume":"285","author":"M Waragai","year":"2009","unstructured":"Waragai M, Okamura N, Furukawa K, Tashiro M, Furumoto S, Funaki Y, et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer\u2019s disease. J Neurol Sci. 2009;285:100\u20138.","journal-title":"J Neurol Sci"},{"key":"2021_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000318754","volume":"30","author":"H Shao","year":"2010","unstructured":"Shao H, Okamura N, Sugi K, Furumoto S, Furukawa K, Tashiro M, et al. Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2010;30:101\u201311.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2021_CR15","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","volume":"355","author":"GW Small","year":"2006","unstructured":"Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652\u201363.","journal-title":"N Engl J Med"},{"key":"2021_CR16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1471-4159.2009.05996.x","volume":"109","author":"PW Thompson","year":"2009","unstructured":"Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer\u2019s disease pathologies. J Neurochem. 2009;109:623\u201330.","journal-title":"J Neurochem"},{"key":"2021_CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"2021_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129\u201335.","journal-title":"Lancet Neurol"},{"key":"2021_CR19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335","journal-title":"Lancet Neurol"},{"key":"2021_CR20","first-page":"387","volume":"53","author":"AP Carpenter Jr","year":"2009","unstructured":"Carpenter Jr AP, Pontecorvo MJ, Hefti FF, Skovronsky DM. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company\u2019s experience. Q J Nucl Med Mol Imaging. 2009;53:387\u201393.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2021_CR21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","volume":"50","author":"SR Choi","year":"2009","unstructured":"Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887\u201394.","journal-title":"J Nucl Med"},{"key":"2021_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"2021_CR23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nucmedbio.2010.02.003","volume":"37","author":"KJ Lin","year":"2010","unstructured":"Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent \u2013 a pilot study. Nucl Med Biol. 2010;37:497\u2013508.","journal-title":"Nucl Med Biol"},{"key":"2021_CR24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med. 2010;51:913\u201320.","journal-title":"J Nucl Med"},{"key":"2021_CR25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404\u201311","journal-title":"Arch Neurol"},{"key":"2021_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.","journal-title":"Arch Neurol"},{"key":"2021_CR27","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1212\/01.wnl.0000279336.36610.f7","volume":"69","author":"M Sarazin","year":"2007","unstructured":"Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69:1859\u201367.","journal-title":"Neurology"},{"key":"2021_CR28","first-page":"77","volume-title":"Geriatric psychiatry","author":"S Mattis","year":"1976","unstructured":"Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, editors. Geriatric psychiatry. New York: Grune & Stratton; 1976. p. 77\u2013121."},{"key":"2021_CR29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.38.6.900","volume":"38","author":"E Grober","year":"1988","unstructured":"Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900\u20133.","journal-title":"Neurology"},{"key":"2021_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/brln.1996.0039","volume":"53","author":"G Deloche","year":"1996","unstructured":"Deloche G, Hannequin D, Dordain M, Perrier D, Pichard B, Quint S, et al. Picture confrontation oral naming: performance differences between aphasics and normals. Brain Lang. 1996;53:105\u201320.","journal-title":"Brain Lang"},{"key":"2021_CR31","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1037\/0022-006X.46.6.1258","volume":"46","author":"CJ Golden","year":"1978","unstructured":"Golden CJ, Hammeke TA, Purisch AD. Diagnostic validity of a standardized neuropsychological battery derived from Luria\u2019s neuropsychological tests. J Consult Clin Psychol. 1978;46:1258\u201365.","journal-title":"J Consult Clin Psychol"},{"key":"2021_CR32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.neurol.2008.11.016","volume":"165","author":"F Mahieux-Laurent","year":"2009","unstructured":"Mahieux-Laurent F, Fabre C, Galbrun E, Dubrulle A, Moroni C. Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients. Rev Neurol (Paris). 2009;165:560\u20137.","journal-title":"Rev Neurol (Paris)"},{"key":"2021_CR33","volume-title":"Manuel: test de copie et de reproduction de m\u00e9moire de figures g\u00e9om\u00e9triques complexes","author":"A Rey","year":"1959","unstructured":"Rey A. Manuel: test de copie et de reproduction de m\u00e9moire de figures g\u00e9om\u00e9triques complexes. Paris: Centre de Psychologie Appliqu\u00e9e; 1959"},{"key":"2021_CR34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0001-6918(65)90024-7","volume":"24","author":"AR Jensen","year":"1965","unstructured":"Jensen AR. Scoring the Stroop test. Acta Psychol. 1965;24:398\u2013408.","journal-title":"Acta Psychol"},{"key":"2021_CR35","volume-title":"Wechsler Memory Scale Revised manual","author":"D Wechsler","year":"1959","unstructured":"Wechsler D. Wechsler Memory Scale Revised manual. San Antonio: The Psychological Corporation; 1987"},{"key":"2021_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"R Reitan","year":"1958","unstructured":"Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Ski. 1958;8:271\u20136.","journal-title":"Percept Mot Ski"},{"key":"2021_CR37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2010.05.001","volume":"37","author":"Y Liu","year":"2010","unstructured":"Liu Y, Zhu L, Pl\u00f6ssl K, Choi SR, Qiao H, Sun X, et al. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer\u2019s disease. Nucl Med Biol. 2010;37:917\u201325","journal-title":"Nucl Med Biol"},{"key":"2021_CR38","unstructured":"R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2011. ISBN 3-900051-07-0. URL http:\/\/www.R-project.org"},{"key":"2021_CR39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131:1630\u201345.","journal-title":"Brain"},{"key":"2021_CR40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jneumeth.2008.05.005","volume":"172","author":"CA Raji","year":"2008","unstructured":"Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer\u2019s disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172:277\u201382.","journal-title":"J Neurosci Methods"},{"key":"2021_CR41","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718\u201325.","journal-title":"Neurology"},{"key":"2021_CR42","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210\u20137.","journal-title":"J Nucl Med"},{"key":"2021_CR43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00702-011-0641-6","volume":"118","author":"G Halliday","year":"2011","unstructured":"Halliday G, Song Y, Harding A. Striatal \u03b2-amyloid in dementia with Lewy bodies but not Parkinson\u2019s disease. J Neural Transm. 2011;118:713\u20139.","journal-title":"J Neural Transm"},{"key":"2021_CR44","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/brain\/awn107","volume":"131","author":"J Koivunen","year":"2008","unstructured":"Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer\u2019s disease. Brain. 2008;131:1845\u201353.","journal-title":"Brain"},{"key":"2021_CR45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00415-009-5396-8","volume":"257","author":"K Furukawa","year":"2010","unstructured":"Furukawa K, Okamura N, Tashiro M, Waragai M, Furumoto S, Iwata R, et al. Amyloid PET in mild cognitive impairment and Alzheimer\u2019s disease with BF-227: comparison to FDG-PET. J Neurol. 2010;257:721\u20137.","journal-title":"J Neurol"},{"key":"2021_CR46","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2009;106:6820\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021_CR47","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.biopsych.2010.05.013","volume":"68","author":"T Grimmer","year":"2010","unstructured":"Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:879\u201384.","journal-title":"Biol Psychiatry"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2021-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T08:51:13Z","timestamp":1497948673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-2021-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-2021-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}